doi: 10.1007/978-3-030-97182-3_7.
- PMID: 35930228
- DOI: 10.1007/978-3-030-97182-3_7
Abstract
Schizophrenia is a psychiatric disorder of neurodevelopmental origin that is thought to result from the combination of genetic and socioenvironmental factors. Several studies have linked the endocannabinoid system with the pathophysiology of schizophrenia. Here, we provide a brief overview of the role of the endocannabinoid system (ECS) in the context of biological processes relevant to schizophrenia, such as neurodevelopment, synaptic plasticity, and brain energy metabolism. We also discuss alterations related to the ECS in schizophrenia and current efforts in both in vivo and in vitro studies that have provided a better understanding of the functioning of this system in the context of the disorder. Finally, we highlighted the modulation of the ECS as a potential for discovering novel therapeutic targets, suggesting new avenues for future research in the field.
Keywords: Animal models, Cannabidiol, Cannabinoids, Cell culture, Schizophrenia
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Endocannabinoid system in the neurodevelopment of GABAergic interneurons: implications for neurological and psychiatric disorders.Rev Neurosci. 2021 Mar 30;32(8):803-831. doi: 10.1515/revneuro-2020-0134. Print 2021 Dec 20.PMID: 33781002 Review.
-
Therapeutic Potential of Cannabinoids in Psychosis.Biol Psychiatry. 2016 Apr 1;79(7):604-12. doi: 10.1016/j.biopsych.2015.11.018. Epub 2015 Nov 28.PMID: 26852073 Review.
-
Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.Int J Mol Sci. 2022 May 15;23(10):5526. doi: 10.3390/ijms23105526.PMID: 35628337 Free PMC article. Review.
-
The Cannabinoid CB1 Receptor in Schizophrenia.Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jun;6(6):646-659. doi: 10.1016/j.bpsc.2020.06.018. Epub 2020 Jul 6.PMID: 33077399 Review.
-
From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.Front Psychiatry. 2021 Jul 5;12:682611. doi: 10.3389/fpsyt.2021.682611. eCollection 2021.PMID: 34290632 Free PMC article. Review.
References
-
- Abel, T., & Nickl-Jockschat, T. (Eds.). (2016). The neurobiology of schizophrenia. Academic Press.
-
- Aguado, T., Monory, K., Palazuelos, J., Stella, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M., & Galve-Roperh, I. (2005). The endocannabinoid system drives neural progenitor proliferation. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 19(12), 1704–1706. – DOI
-
- Aguado, T., Palazuelos, J., Monory, K., Stella, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M., & Galve-Roperh, I. (2006). The endocannabinoid system promotes Astroglial differentiation by acting on neural progenitor cells. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 26(5), 1551–1561. – DOI
-
- Barrera-Conde, M., Ausin, K., Lachén-Montes, M., Fernández-Irigoyen, J., Galindo, L., Cuenca-Royo, A., Fernández-Avilés, C., et al. (2021). Cannabis use induces distinctive proteomic alterations in olfactory Neuroepithelial cells of schizophrenia patients. Journal of Personalized Medicine, 11(3). https://doi.org/10.3390/jpm11030160
